{"entity":{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","aka":["Jubilant Therapeutics Inc."],"tldr":"Jubilant Therapeutics, part of India's Jubilant group, designs small molecules that hit two epigenetic targets at once; JBI-802 inhibits both LSD1 and HDAC6 for myeloproliferative neoplasms and small cell lung cancer.","summary":"Jubilant Therapeutics is a precision-medicine subsidiary of Jubilant Pharmova that uses structure-based design to make dual-action small molecules. JBI-802 is an oral inhibitor of the epigenetic enzymes LSD1 and HDAC6 in a single molecule, in phase 1/2 trials in essential thrombocythaemia, other myeloproliferative neoplasms and neuroendocrine cancers including small cell lung cancer. Its pipeline also includes a PAD4 inhibitor and PD-L1 small molecules.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.jubilanttx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["jbi-802"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Bedminster, New Jersey","country":"US","companyType":"biotech","website":"https://www.jubilanttx.com/","investors":[],"funding":[]},"route":"/companies/jubilant-therapeutics/","neighbours":{"drug":[{"id":"jbi-802","kind":"drug","name":"JBI-802","route":"/drugs/jbi-802/"}]}}